Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bone disorders and inflammatory disease therapeutics - Lakefront Biotherapeutics

Next Previous
Drug Profile

Research programme: bone disorders and inflammatory disease therapeutics - Lakefront Biotherapeutics

Alternative Names: Bone and joint disorder therapeutics - Lakefront Biotherapeutics; GT146; GT328; GT442; Oral psoriasis therapy - Lakefront Biotherapeutics; Osteoporosis therapies - Lakefront Biotherapeutics; Rheumatoid arthritis therapies - Lakefront Biotherapeutics

Latest Information Update: 10 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProSkelia
  • Developer Ghent University; Lakefront Biotherapeutics; Pfizer
  • Class Antibodies; Small molecules
  • Mechanism of Action Integrin inhibitors; Osteogenesis stimulants; Protein kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bone disorders; Inflammation; Osteoporosis; Psoriasis

Most Recent Events

  • 08 May 2026 Galapagos NV is now called Lakefront Biotherapeutics
  • 28 Apr 2021 No recent reports of development identified for preclinical development in Inflammation in Belgium
  • 08 Apr 2019 The programme is still in preclinical phase for Inflammation in Belgium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top